Target intelligence / Profile preview

Premature ovarian failure protein 1B (POF1B)

Target
POF1B
Molecular classification
Other (Actin-binding protein), Cytoskeletal-associated protein (acts at cell junctions in epithelia)
01

Overview

Premature ovarian failure protein 1B (POF1B) is an actin-binding protein encoded by the POF1B gene on the X chromosome, primarily expressed in polarized epithelial tissues and localized to tight junctions and desmosomes. It regulates epithelial monolayer organization through control of the actin cytoskeleton and is essential for tight junction and desmosome assembly, cell polarity, and tissue architecture in epithelia. Genetic variants in POF1B (e.g. R329Q) have been associated with the pathogenesis of premature ovarian failure, likely through impaired binding to nonmuscle actin filaments and altered cytoskeletal dynamics. Its disruption leads to defects in cell adhesion, polarity, and possibly increased ovarian germ-cell apoptosis, resulting in depletion of the ovarian reserve and clinical POF. POF1B is not currently a therapeutic target, and no drugs or small molecules are known to interact with its protein product.

Other names
POF1BPOF2BProtein POF1BPremature ovarian failure protein 1BFLJ22792Premature ovarian failure, 1B
02

Mechanism of action

None reported. No drugs known to target or modulate POF1B

03

Biological functions

Organization of epithelial monolayersRegulation of actin cytoskeletonTight junction assembly in polarised epithelial cellsCell adhesion (desmosomes)Germ-cell division and ovarian development (putative role)Regulation of epithelial polarityPossibly antiapoptotic functions in the ovary
04

Disease associations

Premature ovarian failure (POF)Ovarian dysfunction (putative)
05

Safety considerations

None described, as no drugs or direct therapeutic strategies against POF1B are indicatedMutation is linked to disease risk (POF), not as a drug safety concern
06

Interacting drugs

None known or reported in current literature
07

Biomarkers

Mutations in POF1B (e.g. R329Q) may be researched as genetic biomarkers for susceptibility to premature ovarian failure in clinical genetic testingNo validated protein expression, activity, or circulating biomarkers

Beyond the preview

Go deeper on Premature ovarian failure protein 1B (POF1B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Premature ovarian failure protein 1B (POF1B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call